Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS responds to revocation of the accreditation of the SA Doping Control Laboratory by WADA
2017-07-01

The World Anti-Doping Agency (WADA) yesterday informed the South African Doping Control Laboratory (SADoCoL) at the University of the Free State (UFS) that the WADA accreditation status of the laboratory has been revoked.

This revocation does, however, not include the analysis of blood samples for the Athlete Biological Passport for which SADoCoL has been re-accredited in August 2016 and which the laboratory will continue to perform. It also does not impact at all on the testing of urine sport samples by the South African Institute of Drug-free Sport (SAIDS), who will continue to send such samples for testing to other WADA accredited laboratories, while blood samples will be tested at SADoCoL as before.

The revocation follows a year long period of suspension in which the laboratory had to develop its analytical capabilities and instate new systems and methodologies.  “In this period the laboratory worked diligently to realize all of these requirements and according to an inspection team from the WADA Laboratory Expert Group who visited the laboratory in February 2017, much has been done and the Laboratory is in a much better state than it was before the suspension in May 2016,” says prof Marthinus van der Merwe, Director of SADoCoL.

“However, there were certain aspects of these requirements that the laboratory could not achieve within the time-frame stipulated by WADA and therefore the organisation is bound by its rules and regulations to now revoke the accreditation status of the laboratory. Since much effort and resources have been invested in the laboratory in the last two years, the management of SADoCoL together with senior leadership of the UFS decided to go ahead and finalise all development in order to re-apply for WADA accreditation,” says prof van der Merwe. 

“The UFS fully acknowledges the hard work of SADoCoL during the period of development and is committed to support the laboratory in its endeavors to re-attain its status within the very specialised and highly regulated community of world-wide doping control laboratories.  The premium goal of the laboratory is still to fully serve the sporting community of South Africa and Africa according to the WADA guidelines for anti-doping control in Sport and it is confident to attain that with the support of all role players in this field,” says Prof Witthuhn, Vice-Rector: Research at the UFS.

Released by:
Lacea Loader (Director: Communication and Brand Management)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept